MarketPulse

HS235

2 articles
BenzingaBenzinga··Vandana Singh

GSK Acquires 35Pharma for $950M to Strengthen Pulmonary Hypertension Portfolio

GSK acquires 35Pharma for $950M, adding pulmonary hypertension treatment HS235 to its pipeline. Move strengthens GSK's position in the growing $18B market.
GSKRAPTacquisitionclinical development
BenzingaBenzinga··Globe Newswire

GSK Acquires 35Pharma for $950M to Advance Pulmonary Hypertension Treatment

GSK acquires 35Pharma for $950M to gain HS235, a clinical-stage pulmonary hypertension drug with improved safety profiles versus existing treatments.
GSKacquisitionclinical development